01—Abstract
Summary
Summary of the 10-K/A filed July 31, 2013. Cited figures are marked; the original filing is the authoritative source.
This filing is an amendment (10-K/A) to Amgen Inc.'s previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2012.
The amendment specifically pertains to Exhibit 10.54, a Collaboration and License Agreement between Amgen and Celltech R&D Limited. The company sought confidential treatment for portions of this exhibit and is refiling it with reduced redactions following discussions with the SEC staff. This amendment does not alter other financial information or disclosures from the original 10-K and is primarily administrative in nature, re-establishing the exhibit with revised confidentiality status.
02—Key points
Key Highlights
- This is an Amendment No. 1 to the Form 10-K for the fiscal year ended December 31, 2012.
- The sole purpose of this amendment is to refile Exhibit 10.54, a Collaboration and License Agreement with Celltech R&D Limited, with less redacted information.
- The amendment addresses the confidential treatment of specific portions of Exhibit 10.54, following SEC staff correspondence.
- This filing does not amend any other information or financial statements presented in the original Form 10-K.
- New certifications from the CEO and CFO are included as required by Rule 13a-14(a).
- The amendment supersedes the previously filed version of Exhibit 10.54.
- Amgen Inc. is identified as a large accelerated filer.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Amgen Inc kept $0.25.
- Revenue$17.27B100.0%
- Cost of revenue−$3.20B18.5%
- Gross profit$14.07B81.5%
- Operating costs−$8.49B49.2%
- Operating income$5.58B32.3%
- Interest, other & tax−$1.23B7.1%
- Net income$4.34B25.2%
Where FY2012 revenue went
$17.27B- SG&A: $4.81B, 28% of revenue
- Net income: $4.34B, 25% of revenue
- Other operating costs: $3.67B, 21% of revenue
- Cost of revenue: $3.20B, 19% of revenue
- Interest, other & tax: $1.23B, 7.1% of revenue
Kept 25% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-K/AFY2012filed July 31, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $17.27B$15.58B | +10.8% |
| Cost of Revenue | $3.20B$2.71B | +18.1% |
| Gross Profit | $14.07B$12.87B | +9.3% |
| SG&A Expenses | $4.81B$4.50B | +7.0% |
| Operating Expenses | $11.69B$11.27B | +3.7% |
| Operating Income | $5.58B$4.31B | +29.3% |
| Interest Expense | $1.05B$610.00M | +72.6% |
| Net Income | $4.34B$3.68B | +18.0% |
| EPS (Basic) | $5.61$4.07 | +37.8% |
| EPS (Diluted) | $5.52$4.04 | +36.6% |
| Shares Outstanding (Basic) | 775.00M905.00M | −14.4% |
| Shares Outstanding (Diluted) | 787.00M912.00M | −13.7% |
05—Questions
Frequently Asked Questions
What is the primary reason for this Form 10-K/A filing?
The primary reason for this filing is to amend Exhibit 10.54, a Collaboration and License Agreement with Celltech R&D Limited, by refiling it with reduced redactions. This action was taken after Amgen sought and received guidance from the SEC staff regarding the confidential treatment of certain portions of the agreement.
Does this amendment change Amgen's financial performance for the fiscal year ended December 31, 2012?
No, this amendment is purely administrative and pertains to the disclosure of specific contractual information (Exhibit 10.54). It does not modify or update any of the financial statements or operational disclosures made in the original Form 10-K filing for the year ended December 31, 2012.
What is Exhibit 10.54 about?
Exhibit 10.54 is the Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited, dated May 10, 2002, along with its Amendment No. 1, effective June 9, 2003. This amendment reflects a revised version of this exhibit with less information redacted, as originally requested by Amgen for confidential treatment.
Are there any new financial results or operational updates in this filing?
No, this filing is not intended to provide new financial results or operational updates. It is solely an amendment to correct the redaction level of a specific exhibit related to a prior agreement. All other disclosures from the original Form 10-K remain as filed.
06—Continue